Premium
Roivant Sciences Ltd (ROIV)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -34,48k | 1,12M | Sale to Issuer | 32,41 | 1,36M | -2,47% |
| 2026-05-22 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 5,28M | Derivative Exercise and Sale | 3,85 - 30,27 | 1,36M | - |
| 2026-05-20 | Mr. Richard PulikCFO | -18,96k | 614,56k | Sale to Issuer | 32,41 | 92,46k | -17,02% |
| 2026-04-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 5,15M | Derivative Exercise and Sale | 3,85 - 29,59 | 1,33M | - |
| 2026-04-17 | Mr. Ilan OrenIndependent Chairman | -95,00 | 2,83k | Sale to Issuer | 29,83 | 105,71k | -0,09% |
| 2026-04-17 | Mr. James C. MomtazeeIndependent Director | -94,00 | 2,80k | Sale to Issuer | 29,83 | 94,88k | -0,10% |
| 2026-04-16 | Mr. Matthew GlineCEO & Director | -289,77k | 8,45M | Vente | 29,16 | 82,26k | -77,89% |
| 2026-04-08 | Ms. Jennifer HumesCAO | -13,54k | 384,07k | Vente | 28,37 | 84,19k | -13,85% |
| 2026-03-31 | Dr. Frank M. TortiPresident & Vant Chair | -160,04k | 4,43M | Sale to Issuer | 27,70 | 13,58M | -1,17% |
| 2026-03-30 | Mr. Matthew GlineCEO & Director | -97,32k | 2,63M | Derivative Exercise and Sale | 26,41 - 27,70 | 372,03k | - |
| 2026-03-31 | Mr. Matthew GlineCEO & Director | -261,19k | 7,23M | Sale to Issuer | 27,70 | 372,03k | -41,25% |
| 2026-03-30 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -58,39k | 1,58M | Derivative Exercise and Sale | 26,41 - 27,70 | 18,68M | - |
| 2026-03-31 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -158,93k | 4,40M | Sale to Issuer | 27,70 | 18,68M | -0,84% |
| 2026-03-26 | Ms. Meghan M. FitzGeraldIndependent Director | -70,00k | 1,31M | Derivative Exercise and Sale | 8,80 - 27,45 | 28,44k | - |
| 2026-03-20 | Mr. Richard PulikCFO | -1,55k | 42,82k | Sale to Issuer | 27,70 | 56,97k | -2,64% |
| 2026-03-20 | Ms. Jennifer HumesCAO | -14,53k | 402,37k | Sale to Issuer | 27,70 | 97,73k | -12,94% |
| 2026-03-17 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 4,88M | Derivative Exercise and Sale | 3,85 - 28,24 | 1,33M | - |
| 2026-03-16 | Ms. Melissa B. EpperlyIndependent Director | -41,86k | 1,20M | Vente | 28,68 | 1,28k | -97,03% |
| 2026-02-20 | Mr. Richard PulikCFO | -1 000,00 | 27,15k | Sale to Issuer | 27,15 | 56,76k | -1,73% |
| 2026-02-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 191,43k | Sale to Issuer | 27,15 | 1,33M | -0,53% |
| 2026-02-19 | Dr. Frank M. TortiPresident & Vant Chair | -3,00M | 70,49M | Derivative Exercise and Sale | 3,85 - 27,51 | 13,74M | - |
| 2026-02-13 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 4,53M | Derivative Exercise and Sale | 3,85 - 26,49 | 1,33M | - |
| 2026-02-11 | QVT Financial LPSociété | -1,23M | 32,66M | Vente | 26,49 - 26,76 | 25,16M | -4,65% |
| 2026-02-09 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -651,56k | 8,98M | Derivative Exercise and Sale | 12,68 - 26,47 | 18,84M | - |
| 2026-01-20 | Mr. Ilan OrenIndependent Chairman | -124,00 | 2,85k | Sale to Issuer | 22,98 | 104,90k | -0,12% |
| 2026-01-20 | Mr. James C. MomtazeeIndependent Director | -122,00 | 2,80k | Sale to Issuer | 22,98 | 94,51k | -0,13% |
| 2026-01-20 | Ms. Melissa B. EpperlyIndependent Director | -54,00 | 1,24k | Sale to Issuer | 22,98 | 43,14k | -0,13% |
| 2026-01-12 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,61M | Derivative Exercise and Sale | 3,85 - 21,92 | 1,33M | - |
| 2025-12-29 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -3,20M | 28,90M | Derivative Exercise and Sale | 12,68 - 21,74 | 18,84M | - |
| 2025-12-24 | Dr. Frank M. TortiPresident & Vant Chair | -175,38k | 1,46M | Other Disposition | 22,47 | 0,00 | -100,00% |
| 2025-12-23 | Dr. Eric VenkerPresident & CEO of Immunovant | 156,69k | 603,25k | Derivative Exercise and Retained Stock | 3,85 | 1,33M | 13,37% |
| 2025-12-23 | Dr. Eric VenkerPresident & CEO of Immunovant | -275,00k | 5,12M | Derivative Exercise and Sale | 3,85 - 22,53 | 1,33M | - |
| 2025-12-23 | Mr. Richard PulikCFO | -260,00k | 4,84M | Derivative Exercise and Sale | 3,85 - 22,45 | 52,92k | - |
| 2025-12-23 | Mr. Richard PulikCFO | -146,73k | 3,29M | Vente | 22,39 | 52,92k | -73,49% |
| 2025-12-20 | Mr. Richard PulikCFO | -2,13k | 47,71k | Sale to Issuer | 22,41 | 199,66k | -1,06% |
| 2025-12-17 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -59,51k | 619,53k | Derivative Exercise and Sale | 12,68 - 23,09 | 0,00 | - |
| 2025-12-16 | QVT Financial LPSociété | -1,69M | 39,07M | Vente | 22,93 - 23,17 | 26,39M | -6,03% |
| 2025-12-15 | Mr. Matthew GlineCEO & Director | -3,87M | 36,85M | Derivative Exercise and Sale | 4,06 - 21,68 | 82,26k | - |
| 2025-12-11 | Mr. Vivek RamaswamyInitié | -7,37M | 67,92M | Derivative Exercise and Sale | 12,68 - 22,05 | 47,01M | - |
| 2025-12-11 | Mr. Vivek RamaswamyInitié | -1,00 | 21,64 | Other Disposition | 21,64 | 47,01M | -0,00% |
| 2025-12-09 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,40M | Derivative Exercise and Sale | 3,85 - 20,85 | 1,17M | - |
| 2025-11-20 | Mr. Richard PulikCFO | -1,24k | 25,03k | Sale to Issuer | 20,27 | 197,62k | -0,62% |
| 2025-11-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 142,92k | Sale to Issuer | 20,27 | 1,17M | -0,60% |
| 2025-11-19 | QVT Financial LPSociété | -1,30M | 26,30M | Vente | 20,16 - 20,25 | 28,08M | -4,42% |
| 2025-11-13 | Mr. Vivek RamaswamyInitié | -1,85M | 37,94M | Vente | 20,33 - 20,81 | 47,01M | -3,80% |
| 2025-11-07 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,27M | Derivative Exercise and Sale | 3,85 - 20,22 | 1,17M | - |
| 2025-10-20 | Mr. James C. MomtazeeIndependent Director | -158,00 | 2,80k | Sale to Issuer | 17,74 | 94,02k | -0,17% |
| 2025-10-20 | Mr. Ilan OrenIndependent Chairman | -281,00 | 4,98k | Sale to Issuer | 17,74 | 103,86k | -0,27% |
| 2025-10-15 | Dr. Eric VenkerPresident & CEO of Immunovant | -851,38k | 973,08k | Derivative Exercise and Sale | 15,85 - 17,06 | 1,17M | - |
| 2025-10-09 | Dr. Eric VenkerPresident & CEO of Immunovant | -125,67k | 55,51k | Derivative Exercise and Sale | 15,85 - 16,30 | 1,17M | - |
| 2025-10-06 | Dr. Eric VenkerPresident & CEO of Immunovant | -665,16k | 4,83M | Derivative Exercise and Sale | 3,85 - 16,34 | 1,17M | - |
| 2025-09-28 | Mr. Richard PulikCFO | -2,34k | 35,51k | Sale to Issuer | 15,17 | 196,43k | -1,18% |
| 2025-09-19 | Dr. Eric VenkerPresident & CEO of Immunovant | 1 000,00k | 3,85M | Derivative Exercise and Retained Stock | 3,85 | 1,17M | 601,34% |
| 2025-09-22 | Dr. Eric VenkerPresident & CEO of Immunovant | -562,37k | 6,24M | Derivative Exercise and Sale | 3,85 - 15,01 | 1,17M | - |
| 2025-09-19 | Dr. Eric VenkerPresident & CEO of Immunovant | -1,15M | 17,12M | Vente | 14,83 - 14,95 | 1,17M | -49,62% |
| 2025-09-20 | Mr. Richard PulikCFO | -2,13k | 32,02k | Sale to Issuer | 15,04 | 194,19k | -1,08% |
| 2025-09-18 | Mr. Matthew GlineCEO & Director | 3,32k | 49,96k | Achat | 15,07 | 62,47k | 5,60% |
| 2025-09-10 | Mr. Daniel A. GoldIndependent Director | -5,27k | 72,57k | Other Disposition | 13,77 | 8,95M | -0,06% |
| 2025-09-10 | Mr. James C. MomtazeeIndependent Director | -3,28k | 45,19k | Other Disposition | 13,77 | 93,39k | -3,40% |
| 2025-09-10 | Mr. Ilan OrenIndependent Chairman | -2,04k | 28,13k | Other Disposition | 13,77 | 102,64k | -1,95% |
| 2025-09-10 | Ms. Meghan M. FitzGeraldIndependent Director | -937,00 | 12,90k | Other Disposition | 13,77 | 28,44k | -3,19% |
| 2025-09-10 | Ms. Melissa B. EpperlyIndependent Director | -1,66k | 22,87k | Other Disposition | 13,77 | 41,32k | -3,86% |
| 2025-09-03 | Mr. Vivek RamaswamyInitié | -1,78M | 22,46M | Vente | 12,50 - 12,96 | 48,87M | -3,51% |
| 2025-08-28 | Mr. Richard PulikCFO | -2,34k | 27,94k | Sale to Issuer | 11,94 | 192,15k | -1,20% |
| 2025-08-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 787,00k | Derivative Exercise and Sale | 3,85 - 11,72 | 1,31M | - |
| 2025-08-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 82,64k | Sale to Issuer | 11,72 | 1,31M | -0,53% |
| 2025-08-20 | Mr. Richard PulikCFO | -1,24k | 14,47k | Sale to Issuer | 11,72 | 192,32k | -0,64% |
| 2025-07-28 | Mr. Richard PulikCFO | -1,92k | 21,78k | Sale to Issuer | 11,35 | 191,14k | -0,99% |
| 2025-07-21 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 767,00k | Derivative Exercise and Sale | 3,85 - 11,52 | 1,31M | - |
| 2025-07-17 | Mr. James C. MomtazeeIndependent Director | -241,00 | 2,81k | Sale to Issuer | 11,65 | 80,26k | -0,30% |
| 2025-04-17 | Mr. Ilan OrenIndependent Chairman | -115,00 | 1,34k | Sale to Issuer | 11,65 | 88,28k | -0,13% |
| 2025-06-28 | Mr. Richard PulikCFO | -1,65k | 18,83k | Sale to Issuer | 11,39 | 188,48k | -0,87% |
| 2025-06-25 | QVT Financial LPSociété | -36,76M | 0,00 | Other Disposition | - | 29,38M | -55,58% |
| 2025-06-20 | Mr. Richard PulikCFO | -1,50k | 17,21k | Sale to Issuer | 11,45 | 183,48k | -0,81% |
| 2025-06-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 760,00k | Derivative Exercise and Sale | 3,85 - 11,45 | 1,31M | - |
| 2025-06-18 | Mr. Vivek RamaswamyInitié | -1,14M | 13,08M | Vente | 11,45 - 11,46 | 50,64M | -2,21% |
| 2025-06-04 | Mr. Vivek RamaswamyInitié | -748,23k | 8,45M | Vente | 11,19 - 11,34 | 51,78M | -1,42% |
| 2025-06-02 | Dr. Eric VenkerPresident & CEO of Immunovant | 385,03k | 1,48M | Derivative Exercise and Retained Stock | 3,85 | 1,31M | 41,66% |
| 2025-06-02 | Dr. Eric VenkerPresident & CEO of Immunovant | -1 000,00k | 7,30M | Derivative Exercise and Sale | 3,85 - 11,22 | 1,31M | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
